7,689 Intuitive Surgical, Inc. $ISRG Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,551 shares of the medical equipment provider’s stock after selling 7,689 shares during the quarter. New York Life Investment Management LLC’s holdings in Intuitive Surgical were worth $21,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Main Street Group LTD purchased a new position in shares of Intuitive Surgical during the first quarter valued at approximately $30,000. North Point Portfolio Managers Corp OH purchased a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $27,000. John Boyer Inc. purchased a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $27,000. Compass Wealth Management LLC purchased a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $29,000. Finally, Evergreen Advisors LLC bought a new position in Intuitive Surgical during the 1st quarter valued at approximately $35,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 2.3%

NASDAQ:ISRG opened at $450.04 on Wednesday. The company’s 50 day moving average price is $413.15 and its 200-day moving average price is $431.20. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The stock has a market cap of $156.00 billion, a price-to-earnings ratio of 54.42, a PEG ratio of 3.17 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The firm had revenue of $3.05 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the prior year, the company posted $2.40 earnings per share. The company’s quarterly revenue was up 21.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 4,047 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $453.21, for a total transaction of $1,834,140.87. Following the transaction, the vice president owned 1,026 shares in the company, valued at approximately $464,993.46. This represents a 79.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Wadors sold 1,078 shares of the firm’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $443.80, for a total transaction of $478,416.40. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 39,056 shares of company stock worth $17,585,864. 0.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent research reports. Citigroup lowered their price objective on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Mizuho cut their target price on Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 21st. Zacks Research raised Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 22nd. UBS Group restated a “buy” rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. Finally, Wall Street Zen raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $493.54.

Intuitive Surgical Company Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.